Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Evogene (EVGN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to 873.08%.

  • Evogene's EBITDA Margin fell 5328500.0% to 873.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 275.91%, marking a year-over-year increase of 370800.0%. This contributed to the annual value of 337.17% for FY2024, which is 1328300.0% up from last year.
  • Evogene's EBITDA Margin amounted to 873.08% in Q3 2025, which was down 5328500.0% from 347.4% recorded in Q2 2025.
  • Evogene's EBITDA Margin's 5-year high stood at 97.52% during Q1 2024, with a 5-year trough of 5666.23% in Q3 2021.
  • Over the past 5 years, Evogene's median EBITDA Margin value was 1060.22% (recorded in 2023), while the average stood at 1604.84%.
  • The largest annual percentage gain for Evogene's EBITDA Margin in the last 5 years was 72644200bps (2021), contrasted with its biggest fall of -39089500bps (2021).
  • Quarter analysis of 5 years shows Evogene's EBITDA Margin stood at 2794.86% in 2021, then soared by 79bps to 573.03% in 2022, then tumbled by -130bps to 1319.72% in 2023, then surged by 79bps to 283.49% in 2024, then plummeted by -208bps to 873.08% in 2025.
  • Its last three reported values are 873.08% in Q3 2025, 347.4% for Q2 2025, and 168.82% during Q1 2025.